@neurologyadvisor.bsky.socialElevated levels of exhaled carbon monoxide were inversely associated with the incidence of #ParkinsonDisease, offering a potential explanation for the previously established correlation between #smoking and this neurodegenerative condition.
@jama.comđź“Š Research Summary: For early #ParkinsonDisease, nicotinamide riboside did not support disease modification, and nonmotor symptom burden worsened more than with placebo.
@jama.comAmong patients with early #ParkinsonDisease, treatment with nicotinamide riboside for 52 weeks did not improve clinical outcomes vs placebo and was associated with worse change in overall Movement Disorder Society Unified Parkinson Disease Rating Scale scores. ja.ma/4e4z3af
@camilla-roselli.bsky.socialToday marks the first day of my #MSCAPostdoctoralFellowship at the Paris Brain Institute, in the #GutSense and #PreSyn labsđź§
I’m excited to continue investigating non-motor symptoms in #ParkinsonDisease and the #gut–brain connection.
Stay tuned for this next chapter and new discoveries! 🪰🔬
@neurologie.bsky.social@neurologyadvisor.bsky.socialThe identification of specific pairs and triplets of modifiable and nonmodifiable #risk factors demonstrated a positive additive interaction that significantly increased the likelihood of developing late-onset #ParkinsonDisease.
@springermedicine.com#MedNews - High exhaled carbon monoxide levels may be associated with a significantly decreased risk for #ParkinsonDisease in people who have never smoked, without increasing the risk for smoking-related diseases.
👉️ buff.ly/Qwn67uW
@psychiatryadvisor.bsky.socialBoth remote and face-to-face individual #CBT formats yield sustained reductions in #anxiety and depression among patients with #ParkinsonDisease.
@neurologyadvisor.bsky.socialFlexible-dose #tavapadon significantly improved motor symptoms compared with placebo among patients with early #ParkinsonDisease, although the trial’s short duration limited conclusions about long-term safety and tolerability.